Kanzo

[title in Japanese]

[in Japanese]

1998 Volume 39 Issue 6 Pages 363-365
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.363

JOURNAL FREE ACCESS

Download PDF (614K)
Establishment of a novel ELISA system to detect the anti-LKM1 antibody utilizing the recombinant cytochrome P450IID6 (CYP2D6) antigen.

Naoki HOSOMI, Keiji ARIMA, Kazumi KONO, Kazutaka KUROKOHCHI, Seishiro ...

1998 Volume 39 Issue 6 Pages 366-373
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.366

JOURNAL FREE ACCESS

Show abstractHide abstract

To detect the anti-liver/kidney microsome tyge 1 antibody (anti-LKM1), a novel enzyme-linked immunosorbent assay (ELISA) system was established utilizing the recombinant CYP2D6 antigen and its efficacy was evaluated. Total 432 sera were tested including 317 from patients with various liver diseases [14 from autoimmune hepatitis (AIH) type II, 218 from chronic viral hepatitis C (CH-C), etc.], 15 from patients without liver diseases and 100 sera from healthy blood donors. By indirect immunofluorescence (IIF), the anti-LKM1 was detected in all 14 sera (100.0%) from AIH type II patients and 7 (3.2%) out of 218 cases of CH-C patients. By ELISA, antibodies from AIH type II patients and CH-C patients that the anti-LKM1 was detected by IIF (CH-C/anti-LKM1⁺) showed significantly higher reactivity [AIH type II; p<0.0001, CH-C/anti-LKM1⁺; p<0.0001] . And only 14 cases from AIH type II patients and 7 cases from CH-C/anti-LKM1⁺ patients were shown to be positive for the anti-LKM1 by ELISA. The reactivity of the anti-LKM1 by ELISA and the IIF titer were also well correlated each other [AIH type II; r=0.883, p<0.001, CH-C/anti-LKM1⁺; r=0.927, p<0.005]. Furthermore, these results were confirmed by Western blot analysis. All patients positive for the anti-LKM1 by ELISA were also positive by Western blot. These results indicated that the established ELISA system was effective to detect the anti-LKM1 antibody in sera, from the standpoints of simplicity and mass-screening as well as quantitation.

View full abstract

Download PDF (1452K)
A study of interferon-β and interferon-α combination therapy for patients with chronic hepatitis C, high viral load, and genotype Ib: its efficacy for hepatic function

Toshihiko MIZUTA, Toshiya HARA, Noriko FUKUSHIMA, Ikuko WADA, Iwata OZ ...

1998 Volume 39 Issue 6 Pages 374-378
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.374

JOURNAL FREE ACCESS

Show abstractHide abstract

We studied the efficacy of interferon (IFN) -β and IFN-α combination therapy (β+α group) on virology and hepatic function in patients with chronic hepatitis C, a high viral load (≥10⁴copies/50μl or≥ 1Meq/ml), and genotype 1b. Eight patients received 600MU of IFN-β daily for 9 weeks, followed by 1000 MU of IFN-α three times weekly for 15 weeks. Standard IFN therapy was given in the form of IFN-β to ten patients (β group) and in the form of IFN-α to 16 patients (α group). None of the regimens produced sustained virus eradication. However, serum ALT levels in patients in the β+α group were significantly decreased and the rate of normalization of serum ALT at both 6 and 12 months after the completion of treatment was 75% (6 of 8 patients). By contrast, no decrease in serum ALT levels were observed in either the β group or α group after treatment, and the rates of sustained serum ALT normalization were 10% (1 of 10 patients) and 12.5% (2 of 16 patients), respectively. The platelet number in the patients in the β+α group increased compared with that in patients in the standard-therapy groups. These results suggest that the combination of IFN-β and IFN-α comprised an excellent regimen for improving hepatic function, but provided no additional virological effect over that produced by standard therapy.

View full abstract

Download PDF (920K)
Clinical evaluation of percutaneous ethanol injection therapy (PEIT) to large hepatocellular carcinomas

The experimental and clinical studies of contrast medium-PEIT (CM-PEIT)

Toshifumi NEKOHASHI

1998 Volume 39 Issue 6 Pages 379-389
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.379

JOURNAL FREE ACCESS

Show abstractHide abstract

To evaluate the therapeutic effect of percutaneous ethanol inlection therapy (PEIT) to large hepatocellular carcinomas (HCC) (over 30mm in diameter), we have demonstrated contrast-medium PEIT (CM-PEIT). CM-PEIT is a newly developed methods that HCC nodules are punctured by a needle under ultrasound imaging and inlected with ethanol mixed with water-soluble contrast medium (Iopamidol containing 370mg/ml iodine) (vol/vol: 7/3) (CME). In this study, CM-PEIT was evaluated on experimental and clinical studies.
In elemental study, ethanol at various concentrations (30%, 50%, 70% and 100%) was injected to DAB-induced rat hepatomas. Histological findings of rat hepatomas following the injection of 70% ethanol were similar to those of rat hepatomas injected 100% ethanol. Completely enhanced rat hepatoma nodules on soft X-p tumorgraphy after 70% CME injection was revealed histologically complete necrosis.
In clinical study, CM-PEIT was performed to large HCCs and the therapeutic effect was evaluated by CT tumorgraphy and X-p tumorgraphy. The area spreaded into HCC nodules by 70% CME on CT tumorgraphy was the same as that of histologically complete necrosis on surgical resection or autopsy. Completely enhanced large HCC nodules on X-p tumorgraphy after 70% CME injection showed almost histologically complete necrosis.
These results suggest that CM-PEIT is a new useful method to evaluate the therapeutic effect of PEIT on large HCCs.

View full abstract

Download PDF (8866K)
An autopsied case of AIDS who presented liver dysfunction

Masato TAKAMATSU, Hiroshi YAMAGUCHI, Takeshi HISA

1998 Volume 39 Issue 6 Pages 390-395
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.390

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (6757K)
Diagnostic difficulty in intrabiliary growth type of hepatocellular carcinoma -a case report-

Satoru MATSUYAMA, Kohji MIYAZAKI, Michito MORI, Kenji KITAHARA

1998 Volume 39 Issue 6 Pages 396-400
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.396

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (6596K)
Granulocyte colony-stimulating factor

An autopsy case of hepatocellular carcinoma producing granulocyte colony-stimulating factor

Shinichiro HORI, Jiro TAKEBAYASHI, Tomoko OKAMOTO, Koujun SETSU, Tomon ...

1998 Volume 39 Issue 6 Pages 401-405
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.401

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (5114K)
[title in Japanese]

[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...

1998 Volume 39 Issue 6 Pages 406-407
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.406

JOURNAL FREE ACCESS

Download PDF (354K)
[title in Japanese]

[in Japanese], [in Japanese]

1998 Volume 39 Issue 6 Pages 408-409
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.408

JOURNAL FREE ACCESS

Download PDF (2996K)
[title in Japanese]

[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...

1998 Volume 39 Issue 6 Pages 410-411
Published: June 25, 1998
Released on J-STAGE: November 17, 2009

DOIhttps://doi.org/10.2957/kanzo.39.410

JOURNAL FREE ACCESS

Download PDF (207K)

Register with J-STAGE for free!